Newborn screening is a practice of screening infants soon after birth for certain harmful and potentially fatal diseases that are not apparent at birth. Majority of newborn screening tests are performed by evaluating metabolites and enzyme activity in blood samples that are collected on specified filter paper. Metabolic and other inherited disorders can hamper an infant’s normal mental and physical development in a number of ways. By carrying out a blood test, doctors can inform whether newborns have certain conditions that could lead to disease or impairment in future to their health. Infants who are screened positive undergo additional testing to confirm if they are truly affected with a disease. Follow-up testing is then carried out by geneticists and pediatrician .
Obtain Report Details @ http://www.transparencymarketresearch.com/newborn-screening-market.html
In Many regions healthcare professionals have started to screen infants for hearing loss and congenital heart defects . Screening programs are mainly run by national or state governing bodies with the goal to screen all infants born in the jurisdiction. The number of diseases to be screened is decided by each jurisdiction, and can differ greatly. Newborn screening was initiated in the U.S. as a public health program. The first disorder targeted for newborn screening was phenylketonuria (PKU) that is now implemented in rest of the world.
Newborn screening market can be classified on the basis of:
- Test type
- Blood test
- Hearing test
- By Technology
- Tandem mass spectrometry
- Enzymes and immunoassays
- Mass spectrometry
- DNA-based assays
- Hearing screen technology
- Pulse oximetry
Newborn Screening is an effective public health movement that targets to identify a number of congenital disorders in newborn children. Many of the disorders if not treated early could result in high mortality and morbidity rates. Newborn screening helps in detection of serious and life threatening diseases such as sickle cell disease, biotinidase deficiency, congenital adrenal hyperplasia, congenital hypothyroidism, galactosemia, cystic fibrosis etc. National Institute Of Health had launched a genomic sequencing and newborn screening disorders research program in 2013 to explore the implications, limitations and challenges associated genomic sequencing in newborn babies.
Geographically, the newborn screening market is segmented into four major regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). In terms of geography, North America accounts for the highest market, followed by Europe due to highly developed healthcare industry, high disposable income and increased government support. However, Asia Pacific market is also witnessing a very positive growth due to high rate of development in healthcare industry, investment by major players and increasing government initiative for the control of newborn diseases and developing medical tourism industry.
Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4581
Some of the key players operating in newborn screening market are Bio-Rad Laboratories, BioTek Instruments, Inc., GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc. and ZenTech S.A.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453